Use of JAK Inhibitors in the Treatment of Alopecia Areata

    June 2026 in “ Serbian Journal of Dermatology and Venerology ”
    Ana Segedi, Olivera Levakov
    Studysummary This report highlights that oral Janus kinase inhibitors, including baricitinib, ritlecitinib, deuruxolitinib, and brepocitinib, show promise for treating alopecia areata by promoting substantial hair regrowth with mild-to-moderate side effects, positioning them as a favorable alternative to corticosteroids.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on reference-global.com →
    Discuss this study in the Community →

    Research cited in this study 14

    1. Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1) Journal of the American Academy of Dermatology · 2024
    2. Comparative Efficacy and Safety of JAK Inhibitors in the Treatment of Moderate-to-Severe Alopecia Areata: A Systematic Review and Network Meta-Analysis Frontiers in pharmacology · 2024
    3. Effectiveness of Oral Tofacitinib Treatment on Patients With Moderate-to-Severe Alopecia Areata in Iran Journal of Cosmetic Dermatology · 2023
    4. Baricitinib for the Treatment of Alopecia Areata Drugs · 2023
    5. Alopecia Areata: An Updated Review for 2023 Journal of Cutaneous Medicine and Surgery · 2023
    6. Efficacy and Safety of Different JAK Inhibitors in the Treatment of Alopecia Areata: A Network Meta-Analysis Frontiers in immunology · 2023
    7. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials American Journal of Clinical Dermatology · 2023
    8. Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway Indian Dermatology Online Journal · 2023
    9. Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study Frontiers in Medicine · 2022
    10. Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers ˆThe ‰journal of allergy and clinical immunology/Journal of allergy and clinical immunology/˜The œjournal of allergy and clinical immunology · 2021
    11. Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management Clinical Reviews in Allergy & Immunology · 2021
    12. Sublingual Tofacitinib for Alopecia Areata: A Roll-Over Pilot Clinical Trial and Analysis of Pharmacokinetics International Journal of Dermatology · 2021
    13. Hair Follicle Immune Privilege and Its Collapse in Alopecia Areata Experimental dermatology · 2020
    14. Alopecia Areata: A Review of Disease Pathogenesis British journal of dermatology/British journal of dermatology, Supplement · 2018